Relenza (Zanamivir) News and Research

RSS

Relenza (zanamivir) is an anti-viral drug, for persons aged 7 years and older for the treatment of uncomplicated influenza illness. This product is approved to treat type A and B influenza, the two types most responsible for flu epidemics. Clinical studies showed that for the drug to be effective, patients needed to start treatment within two days of the onset of symptoms. The drug seemed to be less effective in patients whose symptoms weren't severe or didn't include a fever. Relenza is approved for preventive use, to decrease the risk of developing influenza illness, for persons aged 5 and older. Relenza is a powder that is inhaled twice a day for five days from a breath-activated plastic device called a Diskhaler for treatment of influenza. For preventive use to reduce the risk of getting influenza, Relenza is inhaled once daily for 10 to 28 days as prescribed by a healthcare provider.

Vietnamese researchers say bird flu already resisant to Tamiflu

Scientists in Vietnam are concerned that the deadly bird flu may have infected two more people, and they suspect the virus may have mutated into a more dangerous form which could spread in mammals, and cause outbreaks in poultry.

15 Nov 2005

George Bush needs more money to cope with bird flu

U.S. President George Bush is about to reveal his plans to fight a flu pandemic and apparently he will ask Congress for funding for a vaccine against bird flu as well as infrastructure to deal with any pandemic.

31 Oct 2005

Counterfeit Tamiflu drug a very real threat

Health officials in the U.S. have expressed concern that with the current panic in many countries regarding bird flu, a counterfeit industry to produce the drug Tamiflu may already be in existence.

25 Oct 2005

Avian flu and planning for pandemic

Influenza season is almost upon us. While it is impossible to tell whether we are going to experience a usual flu season -- with one in every five people falling ill -- or whether we are facing a more serious problem such as a dangerous new strain capable of causing a global pandemic, information is important.

20 Oct 2005

As Europe panics, global co-operation urged in the fight against birdflu

As the panic about bird flu spreads across Europe, EU foreign ministers are urging global cooperation in efforts to tackle the threat of the deadly virus.

19 Oct 2005

Drug company donates bird flu vaccine to World Health Organization

A donation by Swiss drug maker Roche, of enough of its Tamiflu antiviral drug to treat 3 million people against birdflu, could slow the spread of the outbreak among humans, especially in countries too poor to afford their own stockpile.

24 Aug 2005

Governments should consider stockpiling zanamivir (Relenza) for flu pandemics

Governments should consider stockpiling zanamivir as an anti-influenza agent in their pandemic plans, states a Comment in this week’s issue of The Lancet.

11 Aug 2005

Scientists have a plan to prevent bird flu pandemic

According to scientists the H5N1 strain of bird flu circulating in Asia which could mutate into a lethal strain and cause a pandemic, could be contained.

4 Aug 2005

Biota's potential damages claim against GlaxoSmithKline could be as high as $430 million

Biota Holdings Limited of Melbourne, Australia, has announced its Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support Biota’s influenza drug, Relenza. The damages assessment was filed with the Victorian Supreme Court and estimates Biota’s losses in the range of $308 million to $430 million.

26 Jul 2005

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

A Supreme Court judge in Melbourne, Australia has described as "high-handed" the delay by global pharmaceutical firm GlaxoSmithKline (GSK) in filing a defence against legal action from Biota Holdings last Friday.

1 May 2005

State-of-the-art computer technology to tackle deadly diseases such as influenza

Researchers at the University of Bath have won a £261,000 grant to use the latest software to produce a blueprint of a designer drug that could stop influenza and some other diseases from replicating in humans.

22 Feb 2005